DUPIXENT (dupilumab), non-corticosteroid dermatitis medicine
Reason for request
High clinical benefit in the treatment of moderate to severe atopic dermatitis (AD) in adults, requiring systemic treatment, only in the event of failure, intolerance or contraindication to cyclosporine and moderate therapeutic progress in the therapeutic strategy
Insufficient clinical benefit to justify its reimbursement for moderate to severe atopic dermatitis in adults, following failure of topical treatments and in systemic treatment-naive patients, failing any robust comparative data versus oral cyclosporine
DUPIXENT has been granted marketing authorisation for the treatment of moderate to severe atopic dermatitis (AD) in adults, requiring systemic treatment.
It has high clinical benefit only as second-line treatment after cyclosporine failure, intolerance or contraindication.
In systemic treatment-naive patients, its clinical benefit is insufficient, failing robust comparative data versus cyclosporine.
Clinical Added Value